{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:55:34Z","timestamp":1776207334125,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.esmoop.2021.100078","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T20:55:44Z","timestamp":1616100944000},"page":"100078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 \u2265 50% advanced non-small-cell lung cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"G.L.","family":"Banna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.L.","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Pizzutilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Genova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Di Noia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gelibter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Macerelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rastelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"De Tursi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Di Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mansueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zoratto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Filetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Montrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Citarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"D'Argento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Buti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Minuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Landi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Guaitoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lo Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"De Toma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Donisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Friedlaender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"De Giglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Metro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Porzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ficorella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100078_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2018.06.016","article-title":"Immune-checkpoint inhibitors in non-small cell lung cancer: a tool to improve patients' selection","volume":"129","author":"Banna","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100078_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100078_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fonc.2019.00264","article-title":"Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis","volume":"9","author":"Addeo","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2021.100078_bib4","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100078_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100078_bib6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamaoncol.2019.0626","article-title":"Tumor mutation burden-from hopes to doubts","volume":"5","author":"Addeo","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2021.100078_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fmed.2019.00172","article-title":"The promise of digital biopsy for the prediction of tumor molecular features and clinical outcomes associated with immunotherapy","volume":"6","author":"Banna","year":"2019","journal-title":"Front Med"},{"key":"10.1016\/j.esmoop.2021.100078_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fonc.2019.00295","article-title":"A\u00a0novel paradigm between leukocytosis, G-CSF secretion, neutrophil-to-lymphocyte ratio, myeloid-derived suppressor cells, and prognosis in non-small cell lung cancer","volume":"9","author":"Tavakkoli","year":"2019","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100078_bib9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100078_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.05.005","article-title":"Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies","volume":"58","author":"Mei","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100078_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2021.100078_bib12","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.21037\/tlcr-19-583","article-title":"Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab","volume":"9","author":"Banna","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100078_bib13","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s12094-020-02337-3","article-title":"Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy","volume":"22","author":"Banna","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100078_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2017.10.014","article-title":"The significance of the PD-L1 expression in non-small-cell lung cancer: trenchant double swords as predictive and prognostic markers","volume":"19","author":"Takada","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"10183","key":"10.1016\/j.esmoop.2021.100078_bib15","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100078_bib16","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100078_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2021.100078_bib18","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-020-02613-9","article-title":"Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of >\/= 50%","volume":"69","author":"Cortellini","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.esmoop.2021.100078_bib19","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.cllc.2020.06.010","article-title":"Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression >\/= 50% and their relationship with clinical outcomes","volume":"21","author":"Cortellini","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100078_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100078_bib21","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0895-4356(03)00207-5","article-title":"External validation is necessary in prediction research: a clinical example","volume":"56","author":"Bleeker","year":"2003","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100078_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100078_bib23","first-page":"120","article-title":"First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy","volume":"7","author":"Zhou","year":"2019","journal-title":"J\u00a0Immun Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100078_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cllc.2019.05.009","article-title":"First-line pembrolizumab versus pembrolizumab plus chemotherapy versus chemotherapy alone in non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"20","author":"Kim","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100078_bib25","doi-asserted-by":"crossref","first-page":"e000457","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Fuca","year":"2019","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100078_bib26","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/bjc.2015.180","article-title":"Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients","volume":"112","author":"Ferrucci","year":"2015","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100078_bib27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/annonc\/mdw016","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"27","author":"Ferrucci","year":"2016","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2021.100078_bib28","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100078_bib29","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00262-014-1545-8","article-title":"Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma","volume":"63","author":"Simeone","year":"2014","journal-title":"Cancer Immunol Immunother"}],"updated-by":[{"DOI":"10.1016\/j.esmoop.2021.100137","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000}}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292100034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292100034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T04:42:54Z","timestamp":1658119374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292100034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S205970292100034X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100078","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 \u2265 50% advanced non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100078"}}